Novel estrogen receptor alpha promoter polymorphism increases ventricular hypertrophic response to hypertension

Journal of Steroid Biochemistry and Molecular Biology

Volumn 103, Issue 2, 2007, Pages 110-118

  Figtree, G A ^a,c   Kindmark, A ^b   Lind, L ^b   Grundberg, E ^b   Speller, B ^c   Robinson, B G ^c   Channon, K M ^a   Watkins, H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aldosterone; Gender differences; Genetic association studies; Hypertrophy remodelling; Sex hormones

Indexed keywords

ADENINE; ESTROGEN RECEPTOR ALPHA; GLUTAMIC ACID; GUANINE; ISOPROTEIN; MESSENGER RNA;

ADULT; ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA FLANKING REGION; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HEART VENTRICLE SIZE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SEQUENCE ANALYSIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; ALTERNATIVE SPLICING; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETIC SCREENING; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 33846411497     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.09.035     Document Type: Article

References (35)

1. Hayward C.S., Webb C.M., and Collins P. Effect of sex hormones on cardiac mass. Lancet 357 (2001) 1354-1356
2. Marcus R., Krause L., Weder A.B., Dominguez-Meja A., Schork N.J., and Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 90 (1994) 928-936
3. Gardin J.M., Siscovick D., Anton-Culver H., Lynch J.C., Smith V.E., Klopfenstein H.S., Bommer W.J., Fried L., O'Leary D., and Manolio T.A. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. Circulation 91 (1995) 1739-1748
4. Light K.C., Hinderliter A.L., West S.G., Grewen K.M., Steege J.F., Sherwood A., and Girdler S.S. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J. Hypertens. 19 (2001) 269-278
5. Miya Y., Sumino H., Ichikawa S., Nakamura T., Kanda T., Kumakura H., Takayama Y., Mizunuma H., Sakamaki T., and Kurabayashi M. Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hypertens. Res. 25 (2002) 153-159
6. Lim W.K., Wren B., Jepson N., Roy S., and Caplan G. Effect of hormone replacement therapy on left ventricular hypertrophy. Am. J. Cardiol. 83 A9 (1999) 1132-1134
7. Modena M.G., Muia Jr. N., Aveta P., Molinari R., and Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 34 (1999) 1041-1046
8. Grohe C., Kahlert S., Lobbert K., Stimpel M., Karas R.H., Vetter H., and Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 416 (1997) 107-112
9. Ogita H., Node K., Liao Y., Ishikura F., Beppu S., Asanuma H., Sanada S., Takashima S., Minamino T., Hori M., and Kitakaze M. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43 (2004) 237-242
10. van Eickels M., Grohe C., Cleutjens J.P., Janssen B.J., Wellens H.J., and Doevendans P.A. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104 (2001) 1419-1423
11. Dash R., Schmidt A.G., Pathak A., Gerst M.J., Biniakiewicz D., Kadambi V.J., Hoit B.D., Abraham W.T., and Kranias E.G. Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy. Cardiovasc. Res. 57 (2003) 704-714
12. Nuedling S., Kahlert S., Loebbert K., Doevendans P.A., Meyer R., Vetter H., and Grohe C. 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc. Res. 43 (1999) 666-674
13. Proudler A.J., Ahmed A.I., Crook D., Fogelman I., Rymer J.M., and Stevenson J.C. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346 (1995) 89-90
14. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K., and Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med. 328 (1993) 1069-1075
15. Godsland I.F., Gangar K., Walton C., Cust M.P., Whitehead M.I., Wynn V., and Stevenson J.C. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42 (1993) 846-853
16. Ho A.Y., Yeung S.S., and Kung A.W. PvuII polymorphisms of the estrogen receptor alpha and bone mineral density in healthy southern Chinese women. Calcif. Tissue Int. 66 (2000) 405-408
17. Ongphiphadhanakul B., Rajatanavin R., Chanprasertyothin S., Piaseu N., and Chailurkit L. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin. Endocrinol. (Oxf.) 49 (1998) 803-809
18. Salmen T., Heikkinen A.M., Mahonen A., Kroger H., Komulainen M., Saarikoski S., Honkanen R., and Maenpaa P.H. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J. Bone Miner. Res. 15 (2000) 315-321
19. Andersen T.I., Heimdal K.R., Skrede M., Tveit K., Berg K., and Borresen A.L. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum. Genet. 94 (1994) 665-670
20. Parl F.F., Cavener D.R., and Dupont W.D. Genomic DNA analysis of the estrogen receptor gene in breast cancer. Breast Cancer Res. Treat. 14 (1989) 57-64
21. Yaich L., Dupont W.D., Cavener D.R., and Parl F.F. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 52 (1992) 77-83
22. Kikuchi T., Hashimoto N., Kawasaki T., and Uchiyama M. Association of serum low-density lipoprotein metabolism with oestrogen receptor gene polymorphisms in healthy children. Acta Paediatr. 89 (2000) 42-45
23. Schubert E.L., Lee M.K., Newman B., and King M.C. Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J. Steroid Biochem. Mol. Biol. 71 (1999) 21-27
24. Grandien K. Determination of transcription start sites in the human estrogen receptor gene and identification of a novel, tissue-specific, estrogen receptor-mRNA isoform. Mol. Cell Endocrinol. 116 (1996) 207-212
25. Flouriot G., Griffin C., Kenealy M., Sonntag-Buck V., and Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol. Endocrinol. 12 (1998) 1939-1954
26. Snieder H., Harshfield G.A., and Treiber F.A. Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension 41 (2003) 1196-1201
27. Post W.S., Larson M.G., Myers R.H., Galderisi M., and Levy D. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 30 (19971025-) 8
28. Mayosi B.M., Keavney B., Kardos A., Davies C.H., Ratcliffe P.J., Farrall M., and Watkins H. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur. Heart J. 23 (2002) 1963-1971
29. Lind L., Sarabi M., Millgard J., Kahan T., and Edner M. Endothelium-dependent vasodilation and structural and functional changes in the cardiovascular system are dependent on age in healthy subjects. Clin. Physiol. 19 (1999) 400-409
30. Sarabi M., Millgard J., and Lind L. Effects of age, gender and metabolic factors on endothelium-dependent vasodilation: a population-based study. J. Intern. Med. 246 (1999) 265-274
31. Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., Muller-Brunotte R., Nystrom F., Ohman K.P., Osbakken M.D., and Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J. Hypertens. 19 (2001) 1167-1176
32. Malmqvist K., Kahan T., Isaksson H., and Ostergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press 10 (2001) 101-110
33. Casale P.N., Devereux R.B., Milner M., Zullo G., Harshfield G.A., Pickering T.G., and Laragh J.H. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann. Intern. Med. 105 (1986) 173-178
34. Kannel W.B. Left ventricular hypertrophy as a risk factor: the Framingham experience. J. Hypertens. Suppl. 9 (1991) S3-S8
35. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141 (2001) 334-341